CA 15-3: Uses and limitation as a biomarker for breast cancer

Duffy, Michael J.; Evoy, Denis; McDermott, Enda

doi:10.1016/j.cca.2010.08.039

Cited by 275 publications

(205 citation statements)

References 71 publications

Supporting

Mentioning

198

Contrasting

Unclassified

Order By: Relevance

“…CEA is useful for diagnosis of recurrence and prognosis of breast cancer [15,16]. CA15-3 was used in the management of prognosis, metastasis and recurrence in breast cancer patients [17,18]. Preoperative level of CEA and CA15-3 in serum were well known as a significant effect on prognosis of breast cancer [19,20].…”

Section: International Conference On Mechanical Science and Engineerimentioning

confidence: 99%

Clinical Value of Nipple Discharge and Serum Markers of Breast Cancer

Liang¹,

Mou²,

Zhang³

et al. 2016

Proceedings of the 2015 International Conference on Mechanical Science and Engineering

View full text Add to dashboard Cite

Abstract. Serum biomarkers are of diagnostic value and can be used for follow-up and prognostic factors. However, serum protein biomarkers show limited diagnostic sensitivity and specificity in stand-alone assays breast cancer because their levels refect tumor burden. In this study, we reviewed the levels of CA15-3, TSGF, CA125 and CEA both in nipple discharge and serum in 179 cases of breast lesions to assess the clinical value of nipple discharge and serum tumor markers in diagnosis, follow-up and prognostic in breast cancer. Our results indicate that the nipple discharge and serum levels of CA15-3, TSGF, CA125 and CEA in breast carcinomas patients were significantly higher than those in the benign disease (P<0.01). Aditionally, The levels of the four tumor markers in nipple discharge were significantly higher than in the serum (P<0.01). The levels of the four biomarkers in nipple discharge had positive correlation with histological grade, clinical stage, the Ki-67 index, expression of VEGF and HER-2/neu, lymphnode metastas and tumor recurrence (P<0.05, respectively), and negative correlation with the level of ER or PR (P<0.05, respectively). The sensitivity of the four serum tumor markes in combination was only 69.77%, in contrast, the combined detection both in discharge and serum was 97.67%, and the negative predictive value was 99.03%. The sensitivity of combined detection both in nipple discharge and serum were significantly higher than other detection (P<0.05). The four tumor markers in nipple discharge are as novel biomarker in dignosis and judging the prognosis of breast cancer. The dynamic combined detection of the four tumor markers both in nipple discharge and serum are helpful to the stratification of preoperative patients and benefit to better prewarning markers for monitoring their recurrence and metastasis of tumors in clinic, but cannot increase the sensitivity of judging the patients with early breast cancer.

show abstract

Section: International Conference On Mechanical Science and Engineerimentioning

confidence: 99%

Clinical Value of Nipple Discharge and Serum Markers of Breast Cancer

Liang¹,

Mou²,

Zhang³

et al. 2016

Proceedings of the 2015 International Conference on Mechanical Science and Engineering

View full text Add to dashboard Cite

show abstract

“…Breast cancer follow-up for the purpose of early detection of local or metastatic recurrence is predominantly based on clinical examination and bilateral mammography [10]. Though controversial, serum markers are also routinely used by many physicians for this purpose [11,12]. The serum marker that is most strongly associated with local or metastatic recurrent disease in patients suffering from breast cancer is CA15-3.…”

Section: Breast Cancermentioning

confidence: 99%

“…Krause et al [64] performed 11 C-choline PET/CT in a series of 63 prostate carcinoma patients presenting with a biochemical relapse after primary treatment with a mean PSA value of 5.9 ng/mL. The recurrence detection rate was 36 % for a PSA value \1 ng/mL, 43 % for a PSA value 1 to \2 ng/mL, 62 % for a PSA value 2 to \3 ng/mL and 73 % for a PSA value [or = 3 ng/mL.…”

Section: C-choline Pet/ctmentioning

confidence: 99%

Serum tumor markers and PET/CT imaging for tumor recurrence detection

et al. 2012

View full text Add to dashboard Cite

When confronted with a suspicious rise in CA 15.3 in asymptomatic breast cancer patients following primary treatment and negative or equivocal conventional imaging findings, FDG PET/CT allows assessment of the site and extent of the recurring disease with an accuracy of 83 %. Both FDG PET and FDG PET/CT are superior when compared to CT alone for the purpose of recurrence detection in patients suffering from ovarian carcinoma who have completed primary therapy but demonstrate a rising serum CA-125 level. As the global accuracy of CT alone for detection of recurrence of ovarian cancer approximates 80 %, CT scan should be performed upfront to identify the site of recurrence. When confronted with negative or equivocal CT findings, FDG PET alone or FDG PET/CT should be added. In patients with rising erum CEA levels that have undergone primary treatment for a colorectal carcinoma, both FDG PET and FDG PET/ CTs allow detection of tumor recurrence with an accuracy of 95 %, well above that of CT and MRI. Available studies further suggest that FDG/PET findings will affect treatment management in 28-50 % of these patients. The detection rate of both 11C-choline and 18F-choline PET and PET/CT for local, regional, and distant recurrence in prostate carcinoma patients with a biochemical recurrence increases with rising PSA value at the time of imaging and reaches about 75 % in patients with PSA [3 ng/mL. Furthermore, PET and PET/CT with [11C]-and [18F]-choline derivates may be helpful in the clinical setting for optimization of individualized treatment.

show abstract

“…Tumor markers used in screening, treatment, and surveillance of breast cancer are CA 15-3 [23], CA 27.29 [14], carcinoembryonic antigen (CEA) [24], estrogen-receptor (ER) [25,26], progesterone receptor (PR) [25], human epidermal growth factor receptor 2 (HER2) [27], urokinase plasminogen activator (uPA) [28], plasminogen activator inhibitor 1 (PAI-1) [28], and certain multiparameter assays for gene expression (Mammoprint, Onco Type DX etc.) [29].…”

Section: Breast Cancermentioning

confidence: 99%

Organ Specific Tumor Markers: What’s New?

Vaidyanathan

Vasudevan

2011

Ind J Clin Biochem

View full text Add to dashboard Cite

Tumor markers are molecules produced in the body in response to cancer. An ideal tumor marker should have high sensitivity and specificity, should be cheap, and should be easily detected in body fluids. Identification of novel markers is important and it is expected that with the advent of newer technologies, more reliable markers will be discovered. This review discusses the currently available tumor markers for different malignancies.

show abstract

CA 15-3: Uses and limitation as a biomarker for breast cancer

Cited by 275 publications

References 71 publications

Clinical Value of Nipple Discharge and Serum Markers of Breast Cancer

Clinical Value of Nipple Discharge and Serum Markers of Breast Cancer

Serum tumor markers and PET/CT imaging for tumor recurrence detection

Organ Specific Tumor Markers: What’s New?

Contact Info

Product

Resources

About